The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody
Open accessAbstract
The hyperpermeability of tumor vessels to macromolecules, compared with normal vessels, is presumably due to vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) released by neoplastic and/or host cells. In addition, VEGF/VPF is a potent angiogenic factor. Removal of this growth factor may reduce the permeability and inhibit tumor angiogenesis. To test these hypotheses, we transplanted a human glioblastoma (U87), a human colon adenocarcinoma (LS174T), and a human melanoma (P-MEL) into two locations in immunodeficient mice: the cranial window and the dorsal skinfold chamber. The mice bearing vascularized tumors were treated with a bolus (0.2 ml) of either a neutralizing antibody (A4.6.1) (492 μg/ml) against VEGF/VPF or PBS (control). We found that tumor vascular permeability to albumin in antibody-treated groups was lower than in the matched controls and that the effect of the antibody was time-dependent and influenced by the mode of injection. Tumor vascular permeability did not respond to i.p. injection of the antibody until 4 days posttreatment. However, the permeability was reduced within 6 h after i.v. injection of the same amount of antibody. In addition to the reduction in vascular permeability, the tumor vessels became smaller in diameter and less tortuous after antibody injections and eventually disappeared from the surface after four consecutive treatments in U87 tumors. These results demonstrate that tumor vascular permeability can be reduced by neutralization of endogenous VEGF/VPF and suggest that angiogenesis and the maintenance of integrity of tumor vessels require the presence of VEGF/VPF in the tissue microenvironment. The latter finding reveals a new mechanism of tumor vessel regression—i.e., blocking the interactions between VEGF/VPF and endothelial cells or inhibiting VEGF/VPF synthesis in solid tumors causes dramatic reduction in vessel diameter, which may block the passage of blood elements and thus lead to vascular regression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,117
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell-Braxton, L., Hillan, K. J., & Moore, M. W. (1996) · Nature · doi:10.1038/380439a0 · Cited by 3,628
Self-citationKim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Self-citationDvorak, H. F., Brown, L. F., Detmar, M. J., & Dvořàk, A. M. (1995) · Europe PMC (PubMed Central) · Cited by 3,115
Holmgren, L., O'Reilly, M. S., & Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0295-149 · Cited by 1,878
Alon, T., Hemo, I., Itin, A., Pe'er, J., Stone, J., & Keshet, E. (1995) · Nature Medicine · doi:10.1038/nm1095-1024 · Cited by 1,604
Traffic Signals on Endothelium for Lymphocyte Recirculation and Leukocyte Emigration
Springer, T. A. (1995) · Annual Review of Physiology · doi:10.1146/annurev.ph.57.030195.004143 · Cited by 1,496
Determinants of tumor blood flow: a review.
Jain, R. K. (1988) · PubMed · Cited by 1,379
Self-citationTakahashi, Y., Kitadai, Y., Bucana, C. D., Cleary, K. R., & Ellis, L. M. (1995) · PubMed · Cited by 1,265
Roberts, W. G., & Palade, G. E. (1995) · Journal of Cell Science · doi:10.1242/jcs.108.6.2369 · Cited by 1,033
Cited by
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Self-citationNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Self-citationThe Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Self-citationVascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Self-citationDelivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Self-citationRole of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,007
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
“VEGF-dependence has been demonstrated in endothelial cells of newly formed, but not of established, vessels within tumour”
BackgroundSelf-citationRole of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502
Self-citationRegulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Self-citationNormalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Self-citationGerber, H.-P., Vu, T. H., Ryan, A. M., Kowalski, J., Werb, Z., & Ferrara, N. (1999) · Nature Medicine · doi:10.1038/9467 · Cited by 2,085
Self-citationGerber, H.-P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B. A., Dixit, V., & Ferrara, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.46.30336 · Cited by 1,981
Self-citationWillett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Self-citationBatchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Self-citationPrinciples and mechanisms of vessel normalization for cancer and other angiogenic diseases
Carmeliet, P., & Jain, R. K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3455 · Cited by 1,675
Self-citationNormalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
Self-citationAntiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
“A variety of preclinical studies using direct and indirect AA agents supported the normalization hypothesis (Izumi et al., 2002; Jain et al., 1998; Tong et al., 2004; Winkler et al., 2004; Yuan et al., 1996).”
Self-citationNishida, N., Yano, H., Nishida, T., Kamura, T., & Kojiro, M. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.3.213 · Cited by 1,434
Jain, R. K., di Tomaso, E., Duda, D. G., Loeffler, J. S., Sorensen, A. G., & Batchelor, T. T. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2175 · Cited by 1,405
Self-citationNormalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248
Self-citationBenjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,241
Tong, R. T., Boucher, Y., Kozin, S. V., Winkler, F., Hicklin, D. J., & Jain, R. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0074 · Cited by 1,189
Self-citationKinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation
Winkler, F., Kozin, S. V., Tong, R. T., Chae, S.-S., Booth, M. F., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., di Tomaso, E., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.011 · Cited by 1,170
Self-citationKlement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Molecular and biological properties of vascular endothelial growth factor
Ferrara, N. (1999) · Journal of Molecular Medicine · doi:10.1007/s001099900019 · Cited by 1,158
Self-citationRole of vascular endothelial growth factor in regulation of physiological angiogenesis
Ferrara, N. (2001) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2001.280.6.c1358 · Cited by 1,085
Self-citationNishiyama, N., & Kataoka, K. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.05.006 · Cited by 1,052
Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response
Dewhirst, M. W., Cao, Y., & Moeller, B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2397 · Cited by 1,022
Clinical applications of angiogenic growth factors and their inhibitors
Ferrara, N., & Alitalo, K. (1999) · Nature Medicine · doi:10.1038/70928 · Cited by 1,004
Self-citationGerber, H.-P., Dixit, V., & Ferrara, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.21.13313 · Cited by 981
Self-citationBevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
Ferrara, N., Hillan, K. J., & Novotny, W. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.132 · Cited by 977
Self-citationVEGF is required for growth and survival in neonatal mice
Gerber, H.-P., Hillan, K. J., Ryan, A. M., Kowalski, J., Keller, G.-A., Rangell, L., Wright, B. D., Radtke, F., Aguet, M., & Ferrara, N. (1999) · Development · doi:10.1242/dev.126.6.1149 · Cited by 915
Self-citationPathophysiological consequences of VEGF-induced vascular permeability
Weis, S. M., & Cheresh, D. A. (2005) · Nature · doi:10.1038/nature03987 · Cited by 909
Miles, D. W., Chan, A., Dirix, L. Y., Cortés, J., Pivot, X., Tomczak, P., Delozier, T., Sohn, J. H., Provencher, L., Puglisi, F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6457 · Cited by 897
FERRARA, N., DAMICO, L., SHAMS, N., LOWMAN, H., & KIM, R. (2006) · Retina · doi:10.1097/01.iae.0000242842.14624.e7 · Cited by 849
Self-citationVEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
Kamba, T., Tam, B. Y. Y., Hashizume, H., Haskell, A., Sennino, B., Mancuso, M. R., Norberg, S. M., O'Brien, S. M., Davis, R. B., Gowen, L. C., et al. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00133.2005 · Cited by 775
Delivery of molecular and cellular medicine to solid tumors
Jain, R. K. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.011 · Cited by 774
Self-citationInai, T., Mancuso, M., Hashizume, H., Baffert, F., Haskell, A., Baluk, P., Hu-Lowe, D. D., Shalinsky, D. R., Thurston, G., Yancopoulos, G. D., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63273-7 · Cited by 757
Transport of drugs from blood vessels to tumour tissue
Dewhirst, M. W., & Secomb, T. W. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.93 · Cited by 749
Dvorak, H. F., Nagy, J. A., Feng, D., Brown, L. F., & Dvorak, A. M. (1999) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-59953-8_6 · Cited by 743
Role of vascular endothelial growth factor in the regulation of angiogenesis
Ferrara, N. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00610.x · Cited by 731
Self-citationWedge, S. R., Kendrew, J., Hennequin, L. F., Valentine, P. J., Barry, S. T., Brave, S. R., Smith, N. R., James, N. H., Dukes, M., Curwen, J. O., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4409 · Cited by 714
Kudo, M., Kawamura, Y., Hasegawa, K., Tateishi, R., Kariyama, K., Shiina, S., Toyoda, H., Imai, Y., Hiraoka, A., Ikeda, M., et al. (2021) · Liver Cancer · doi:10.1159/000514174 · Cited by 678
Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization
Fukumura, D., & Jain, R. K. (2007) · Microvascular Research · doi:10.1016/j.mvr.2007.05.003 · Cited by 691
Self-citationTransport of Molecules, Particles, and Cells in Solid Tumors
Jain, R. K. (1999) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.1.1.241 · Cited by 691
Self-citationHypoxia, Clonal Selection, and the Role of HIF-1 in Tumor Progression
Semenza, G. L. (2000) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409230091169186 · Cited by 654
Gerber, H.-P., & Ferrara, N. (2005) · Cancer Research · doi:10.1158/0008-5472.671.65.3 · Cited by 626
Self-citationAntibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance
Thurber, G. M., Schmidt, M. M., & Wittrup, K. D. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.012 · Cited by 624
FERRARA, N. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70064-x · Cited by 623
Self-citationJain, R. K., Tong, R. T., & Munn, L. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4102 · Cited by 612
Self-citationBrown, E. B., Campbell, R. B., Tsuzuki, Y., Xu, L., Carmeliet, P., Fukumura, D., & Jain, R. K. (2001) · Nature Medicine · doi:10.1038/89997 · Cited by 605
Self-citationDissecting tumour pathophysiology using intravital microscopy
Jain, R. K., Munn, L. L., & Fukumura, D. (2002) · Nature Reviews Cancer · doi:10.1038/nrc778 · Cited by 595
Self-citationConsensus guidelines for the use and interpretation of angiogenesis assays
Nowak-Sliwinska, P., Alitalo, K., Allen, E., Anisimov, A., Aplin, A. C., Auerbach, R., Augustin, H. G., Bates, D. O., van Beijnum, J. R., Bender, R. H. F., et al. (2018) · Angiogenesis · doi:10.1007/s10456-018-9613-x · Cited by 590
Self-citationAndresen, T. L., Jensen, S. S., & Jørgensen, K. (2005) · Progress in Lipid Research · doi:10.1016/j.plipres.2004.12.001 · Cited by 580
VEGF as a Therapeutic Target in Cancer
Ferrara, N. (2005) · Oncology · doi:10.1159/000088479 · Cited by 578
Self-citationShaping Cancer Nanomedicine: The Effect of Particle Shape on The In Vivo Journey of Nanoparticles
Toy, R., Peiris, P. M., Ghaghada, K. B., & Karathanasis, E. (2014) · Nanomedicine · doi:10.2217/nnm.13.191 · Cited by 570
Fujio, Y., & Walsh, K. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.23.16349 · Cited by 553
Vascular Endothelial Growth Factor: Molecular and Biological Aspects
Ferrara, N. (1999) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-59953-8_1 · Cited by 533
Self-citationJain, R. K. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00131-9 · Cited by 529
Self-citationCombining two strategies to improve perfusion and drug delivery in solid tumors
Stylianopoulos, T., & Jain, R. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318415110 · Cited by 508
Benjamin, L. E., & Keshet, E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.16.8761 · Cited by 506
Biology and therapeutic targeting of vascular endothelial growth factor A
Pérez-Gutiérrez, L., & Ferrara, N. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00631-w · Cited by 484
Self-citationPhotoswitchable Nanoparticles for Triggered Tissue Penetration and Drug Delivery
Tong, R., Hemmati, H. D., Langer, R., & Kohane, D. S. (2012) · Journal of the American Chemical Society · doi:10.1021/ja211888a · Cited by 477
Multifunctional polymeric micelles for delivery of drugs and siRNA
Jhaveri, A. M., & Torchilin, V. P. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00077 · Cited by 466
FUKUMURA, D., DUDA, D. G., MUNN, L. L., & JAIN, R. K. (2010) · Microcirculation · doi:10.1111/j.1549-8719.2010.00029.x · Cited by 451
Self-citationVascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Niu, G., & Chen, X. (2010) · Current Drug Targets · doi:10.2174/138945010791591395 · Cited by 451
The Role of Vascular Endothelial Growth Factor in Angiogenesis
Ferrara, N., & Gerber, H.-P. (2001) · Acta Haematologica · doi:10.1159/000046610 · Cited by 451
Self-citationGoldman, C. K., Kendall, R. L., Cabrera, G., Soroceanu, L., Heike, Y., Gillespie, G. Y., Siegal, G. P., Mao, X., Bett, A. J., Huckle, W. R., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8795 · Cited by 443
Dickson, P. V., Hamner, J. B., Sims, T. L., Fraga, C. H., Ng, C. Y. C., Rajasekeran, S., Hagedorn, N. L., McCarville, M. B., Stewart, C. F., & Davidoff, A. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0278 · Cited by 441
Selective Inhibition of Vascular Endothelial Growth Factor–Mediated Angiogenesis by Cyclosporin a
Hernández, G. L., Volpert, O. V., Íñiguez, M. A., Lorenzo, E., Martínez-Martínez, S., Grau, R., Fresno, M., & Redondo, J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.5.607 · Cited by 432
Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro
Wang, Y., Fei, D., Vanderlaan, M., & Song, A. (2004) · Angiogenesis · doi:10.1007/s10456-004-8272-2 · Cited by 430
Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice.
Thurston, G., McLean, J. W., Rizen, M., Baluk, P., Haskell, A., Murphy, T. J., Hanahan, D., & McDonald, D. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci965 · Cited by 423
Kotch, L. E., Iyer, N. V., Laughner, E., & Semenza, G. L. (1999) · Developmental Biology · doi:10.1006/dbio.1999.9253 · Cited by 418
Hypoxia-driven selection of the metastatic phenotype
Sullivan, R., & Graham, C. H. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9062-2 · Cited by 410
Quantitative angiogenesis assays: Progress and problems
Jain, R. K., Schlenger, K., Hockel, M., & Yuan, F. (1997) · Nature Medicine · doi:10.1038/nm1197-1203 · Cited by 385
Self-citationMolecular mechanisms of endothelial hyperpermeability: implications in inflammation
Kumar, P., Shen, Q., Pivetti, C. D., Lee, E. S., Wu, M. H., & Yuan, S. Y. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001112 · Cited by 380
Jain, R. K., Safabakhsh, N., Sckell, A., Chen, Y., Jiang, P., Benjamin, L., Yuan, F., & Keshet, E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10820 · Cited by 374
Self-citationBaffert, F., Le, T., Sennino, B., Thurston, G., Kuo, C. J., Hu-Lowe, D., & McDonald, D. M. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00616.2005 · Cited by 374
VEGF: an update on biological and therapeutic aspects
Ferrara, N. (2000) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(00)00153-1 · Cited by 372
Self-citationMathematical modeling of tumor-induced angiogenesis
Mantzaris, N. V., Webb, S., & Othmer, H. G. (2004) · Journal of Mathematical Biology · doi:10.1007/s00285-003-0262-2 · Cited by 362
Anti-VEGF/VEGFR Therapy for Cancer: Reassessing the Target
Sitohy, B., Nagy, J. A., & Dvorak, H. F. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3406 · Cited by 360
Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.
Goel, S., Wong, A. H.-K., & Jain, R. K. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006486 · Cited by 352
Self-citationAngiogenesis—a new target for future therapy
Pandya, N. M., Dhalla, N. S., & Santani, D. D. (2006) · Vascular Pharmacology · doi:10.1016/j.vph.2006.01.005 · Cited by 345
Control of Apoptosis during Angiogenesis by Survivin Expression in Endothelial Cells
O'Connor, D. S., Schechner, J. S., Adida, C., Mesri, M., Rothermel, A. L., Li, F., Nath, A. K., Pober, J. S., & Altieri, D. C. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64742-6 · Cited by 341
Senger, D. R., Perruzzi, C. A., Streit, M., Koteliansky, V. E., de Fougerolles, A. R., & Detmar, M. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64363-5 · Cited by 340
The biology of the combretastatins as tumour vascular targeting agents
TOZER, G. M., KANTHOU, C., PARKINS, C. S., & HILL, S. A. (2002) · International Journal of Experimental Pathology · doi:10.1046/j.1365-2613.2002.00211.x · Cited by 335
Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11
Wildiers, H., Guetens, G., De Boeck, G., Verbeken, E., Landuyt, B., Landuyt, W., de Bruijn, E. A., & van Oosterom, A. T. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601005 · Cited by 334
Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets
Taylor, O. G., Brzozowski, J. S., & Skelding, K. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00963 · Cited by 322
In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft
Nagengast, W. B., de Vries, E. G., Hospers, G. A., Mulder, N. H., de Jong, J. R., Hollema, H., Brouwers, A. H., van Dongen, G. A., Perk, L. R., & Lub-de Hooge, M. N. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.041301 · Cited by 313
The role of VEGF in the regulation of physiological and pathological angiogenesis
Ferrara, N. (2005) · Mechanisms of Angiogenesis · doi:10.1007/3-7643-7311-3_15 · Cited by 312
Self-citationJain, R. K. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00306-6 · Cited by 298
Self-citationArterial versus venous endothelial cells
dela Paz, N. G., & D’Amore, P. A. (2009) · Cell and Tissue Research · doi:10.1007/s00441-008-0706-5 · Cited by 293
Xu, L., Fukumura, D., & Jain, R. K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108347200 · Cited by 281
Self-citationStreit, M., Velasco, P., Brown, L. F., Skobe, M., Richard, L., Riccardi, L., Lawler, J., & Detmar, M. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65140-1 · Cited by 279
Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs
Dubowchik, G. M., & Walker, M. A. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00018-2 · Cited by 277
Identification of molecular subtypes of glioblastoma by gene expression profiling
Mischel, P. S., Shai, R., Shi, T., Horvath, S., Lu, K. V., Choe, G., Seligson, D., Kremen, T. J., Palotie, A., Liau, L. M., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206344 · Cited by 272
Delivery of molecular and cellular medicine to solid tumors
Jain, R. K. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00027-6 · Cited by 271
Self-citationMahooti, N. I., & Madri, J. A. (1998) · Journal of Cell Science · doi:10.1242/jcs.111.24.3621 · Cited by 266
Iodinated blood pool contrast media for preclinical X-ray imaging applications – A review
Hallouard, F., Anton, N., Choquet, P., Constantinesco, A., & Vandamme, T. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.04.066 · Cited by 265
Directed endothelial cell morphogenesis in micropatterned gelatin methacrylate hydrogels
Nikkhah, M., Eshak, N., Zorlutuna, P., Annabi, N., Castello, M., Kim, K., Dolatshahi-Pirouz, A., Edalat, F., Bae, H., Yang, Y., et al. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.08.068 · Cited by 261
Metadata
- Authors
- Yuan, F., Chen, Y., Dellian, M., Safabakhsh, N., Ferrara, N., & Jain, R. K.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1996-12-10
- Volume
- 93
- Issue
- 25
- Pages
- 14765-14770
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2067055586
- Cited by
- 719
- References
- 32
- FWCI
- 9.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.